Peter Sklar

3.8k total citations · 1 hit paper
46 papers, 2.2k citations indexed

About

Peter Sklar is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, Peter Sklar has authored 46 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Infectious Diseases, 32 papers in Virology and 14 papers in Emergency Medicine. Recurrent topics in Peter Sklar's work include HIV Research and Treatment (32 papers), HIV/AIDS drug development and treatment (32 papers) and HIV-related health complications and treatments (14 papers). Peter Sklar is often cited by papers focused on HIV Research and Treatment (32 papers), HIV/AIDS drug development and treatment (32 papers) and HIV-related health complications and treatments (14 papers). Peter Sklar collaborates with scholars based in United States, France and Italy. Peter Sklar's co-authors include Randi Y. Leavitt, Anthony Rodgers, Edwin DeJesus, Mark J. DiNubile, Jeffrey L. Lennox, Michael D. Miller, Adriano Lazzarin, Jing Zhao, Bach-Yen Nguyen and Xia Xu and has published in prestigious journals such as The Lancet, Blood and Neurology.

In The Last Decade

Peter Sklar

43 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

2009 478 citations Jeffrey L. Lennox, Edwin DeJesus et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Sklar United States	24	1.8k	1.4k	553	412	221	46	2.2k
Dominic Labriola United States	12	765 0.4×	655 0.5×	153 0.3×	469 1.1×	116 0.5×	29	1.4k
James L. K. Fletcher United States	20	849 0.5×	1.0k 0.7×	431 0.8×	319 0.8×	91 0.4×	32	1.3k
Anthony T. Podany United States	18	573 0.3×	286 0.2×	135 0.2×	220 0.5×	123 0.6×	54	844
Linda Wittkop France	19	499 0.3×	270 0.2×	110 0.2×	331 0.8×	153 0.7×	80	1.2k
Cathia Soulié France	23	1.4k 0.8×	1.2k 0.8×	136 0.2×	224 0.5×	358 1.6×	98	1.7k
Jodi Anderson United States	16	496 0.3×	735 0.5×	161 0.3×	269 0.7×	230 1.0×	28	1.3k
Janie Eddy United States	10	748 0.4×	643 0.5×	180 0.3×	339 0.8×	66 0.3×	11	1.1k
F. D. Goebel Germany	19	655 0.4×	666 0.5×	405 0.7×	297 0.7×	157 0.7×	52	1.3k
Francesco Montella Italy	16	537 0.3×	522 0.4×	79 0.1×	208 0.5×	139 0.6×	50	932
Daniel Parker United States	13	826 0.5×	1.2k 0.9×	64 0.1×	231 0.6×	398 1.8×	23	1.6k

Countries citing papers authored by Peter Sklar

Since Specialization

Citations

This map shows the geographic impact of Peter Sklar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Sklar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Sklar more than expected).

Fields of papers citing papers by Peter Sklar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Sklar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Sklar. The network helps show where Peter Sklar may publish in the future.

Co-authorship network of co-authors of Peter Sklar

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Sklar. A scholar is included among the top collaborators of Peter Sklar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Sklar. Peter Sklar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mounzer, Karam, Jihad Slim, Moti Ramgopal, et al.. (2025). Efficacy and Safety of Bictegravir Plus Lenacapavir: 48-Week Outcomes in People With HIV-1 Who Are Virologically Suppressed on Complex Antiretroviral Regimens at Baseline. Open Forum Infectious Diseases. 12(11). ofaf615–ofaf615.

Mounzer, Karam, Jihad Slim, Moti Ramgopal, et al.. (2024). Étude de phase 2 évaluant l'association BIC + LEN en prise orale quotidienne chez des personnes ayant un traitement du VIH par plusieurs comprimés. 3(2). S136–S136. 1 indexed citations

Mounzer, Karam, Jihad Slim, Moti Ramgopal, et al.. (2024). Efficacy and Safety of Switching to Daily Bictegravir Plus Lenacapavir From a Complex HIV Treatment Regimen: A Randomized, Open-Label, Multicenter Phase 2 Study (ARTISTRY-1). Clinical Infectious Diseases. 80(4). 881–888. 3 indexed citations

DeJesus, Edwin, Jean‐Michel Molina, Yazdan Yazdanpanah, et al.. (2020). Islatravir safety analysis through week 48 from a phase 2 trial in treatment naive adults with HIV-1 infection. Journal of the International AIDS Society. 2 indexed citations

Stocchi, Fabrizio, Olivier Rascol, Robert A. Hauser, et al.. (2014). Phase-3 Clinical Trial of the Adenosine 2a Antagonist Preladenant, Given as Monotherapy, in Patients with Parkinson’s Disease (S7.004). Neurology. 82(10_supplement). 4 indexed citations

Hauser, Robert A., Fabrizio Stocchi, Olivier Rascol, et al.. (2014). Phase-3 Clinical Trials of Adjunctive Therapy with Preladenant, an Adenosine 2a Antagonist, in Patients with Parkinson’s Disease (P7.087). Neurology. 82(10_supplement). 9 indexed citations

Sulkowski, Mark, Stanislas Pol, Josep Mallolas, et al.. (2013). Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. The Lancet Infectious Diseases. 13(7). 597–605. 142 indexed citations

Rockstroh, Jürgen K., Edwin DeJesus, Jeffrey L. Lennox, et al.. (2013). Durable Efficacy and Safety of Raltegravir Versus Efavirenz When Combined With Tenofovir/Emtricitabine in Treatment-Naive HIV-1–Infected Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes. 63(1). 77–85. 167 indexed citations

DeJesus, Edwin, Jürgen K. Rockstroh, Jeffrey L. Lennox, et al.. (2012). Efficacy of Raltegravir Versus Efavirenz When Combined With Tenofovir/ Emtricitabine in Treatment-Naïve HIV-1–Infected Patients: Week-192 Overall and Subgroup Analyses From STARTMRK. HIV Clinical Trials. 13(4). 228–232. 26 indexed citations

10.

Teppler, Hedy, Deborah D. Brown, Randi Y. Leavitt, et al.. (2011). Long-Term Safety from the Raltegravir Clinical Development Program. Current HIV Research. 9(1). 40–53. 30 indexed citations

11.

Rockstroh, Jürgen K., Jeffrey L. Lennox, Edwin DeJesus, et al.. (2011). Long-term Treatment With Raltegravir or Efavirenz Combined With Tenofovir/Emtricitabine for Treatment-Naive Human Immunodeficiency Virus-1–Infected Patients: 156-Week Results From STARTMRK. Clinical Infectious Diseases. 53(8). 807–816. 139 indexed citations

12.

Rockstroh, Jürgen K., Hedy Teppler, Jing Zhao, et al.. (2011). Clinical efficacy of raltegravir against B and non-B subtype HIV-1 in phase III clinical studies. AIDS. 25(11). 1365–1369. 23 indexed citations

13.

Nguyen, Bach‐Yen, Robin Isaacs, Hedy Teppler, et al.. (2011). Raltegravir: the first HIV‐1 integrase strand transfer inhibitor in the HIV armamentarium. Annals of the New York Academy of Sciences. 1222(1). 83–89. 41 indexed citations

14.

Lennox, Jeffrey L., Edwin DeJesus, Daniel S Berger, et al.. (2010). Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1–Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses. JAIDS Journal of Acquired Immune Deficiency Syndromes. 55(1). 39–48. 194 indexed citations

15.

Lennox, Jeffrey L., Edwin DeJesus, Adriano Lazzarin, et al.. (2009). Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. The Lancet. 374(9692). 796–806. 478 indexed citations breakdown →

16.

Sereti, Irini, Peter Sklar, Meena S. Ramchandani, et al.. (2007). CD4⁺T Cell Responses to Interleukin‐2 Administration in HIV‐Infected Patients Are Directly Related to the Baseline Level of Immune Activation. The Journal of Infectious Diseases. 196(5). 677–683. 10 indexed citations

17.

Grubb, Jessica R., André Dejam, Jocelyn Voell, et al.. (2006). Lopinavir‐Ritonavir: Effects on Endothelial Cell Function in Healthy Subjects. The Journal of Infectious Diseases. 193(11). 1516–1519. 26 indexed citations

18.

Betz, Marian E., Kelly A. Gebo, Peter Sklar, et al.. (2005). Patterns of Diagnoses in Hospital Admissions in a Multistate Cohort of HIV-Positive Adults in 2001. Medical Care. 43(9). III–3. 45 indexed citations

19.

Sklar, Peter, et al.. (2004). Five-year follow-up of a cohort of profoundly immunosuppressed patients discontinuing therapy for cytomegalovirus retinitis. AIDS. 18(3). 567–569. 6 indexed citations

20.

Dybul, Mark, Marybeth Daucher, Kurt Hertogs, et al.. (2003). Long‐Cycle Structured Intermittent versus Continuous Highly Active Antiretroviral Therapy for the Treatment of Chronic Infection with Human Immunodeficiency Virus: Effects on Drug Toxicity and on Immunologic and Virologic Parameters. The Journal of Infectious Diseases. 188(3). 388–396. 62 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact